Alcohol and Alcoholism Vol. 35, No. 5, pp. 478-492, 2000
© 2000 Medical Council on Alcoholism
THE LONG-TERM COST-EFFECTIVENESS OF IMPROVING ALCOHOL ABSTINENCE WITH ADJUVANT ACAMPROSATE
IMIB, Institute for Medical Informatics and Biostatistics, Riehen, Switzerland,
1 Merk–Lipha S.A., Lyon, France and
2 Department of Gastroenterology, Kent and Sussex Hospital, Tunbridge Wells, UK
Received 13 January 2000; first review notified 6 April 2000; accepted 19 April 2000
A computer model was developed with decision analysis software to explore the long-term clinical and economic outcomes of alcohol abstinence maintenance with either standard counselling therapy or standard therapy plus 48 weeks of adjuvant acamprosate in detoxified alcoholic patients. Important complications of alcoholism were modelled using Markov processes, and included relapse (return to drinking), alcohol-related hepatic disease, acute and chronic pancreatitis, acute and chronic gastritis, oropharyngeal carcinoma, oesophageal carcinoma, alcoholic cardiomyopathy, alcohol-related peripheral neuropathy, alcoholic psychosis, accidental death, and suicide. Probabilities of developing complications were dependent on whether the patients within the cohort remained abstinent or had relapsed. Relapse rates, probabilities, and costs for acamprosate therapy and treatment of complications were taken from published literature. The analysis was performed from the German health insurance perspective. Life expectancy and total lifetime costs (costs of initial abstinence maintenance therapy plus costs of complications) were calculated for a typical male cohort with average age of 41 years, 80% with fatty liver, 15% with cirrhosis, 22% with chronic pancreatitis, and 1% with alcoholic cardiomyopathy at baseline. Life expectancy with and without acamprosate therapy was 15.90 and 14.70 years respectively, and discounted (5% per annum) average total lifetime costs per patient were DEM 46 448 and DEM 49 549 respectively. We conclude that, despite the acquisition costs of DEM 2177, adjuvant acamprosate therapy was both clinically and economically attractive under conservative assumptions.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. A. Zarkin, J. W. Bray, A. Aldridge, D. Mitra, M. J. Mills, D. J. Couper, R. A. Cisler, and for the COMBINE Cost-Effectiveness Research Group Cost and Cost-effectiveness of the COMBINE Study in Alcohol-Dependent Patients Arch Gen Psychiatry, October 1, 2008; 65(10): 1214 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. MORTIMER and L. SEGAL ECONOMIC EVALUATION OF INTERVENTIONS FOR PROBLEM DRINKING AND ALCOHOL DEPENDENCE: COST PER QALY ESTIMATES Alcohol Alcohol., November 1, 2005; 40(6): 549 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. POLDRUGO, D.-A. HAEGER, S. COMTE, J. WALBURG, and A. J. PALMER A CRITICAL REVIEW OF PHARMACOECONOMIC STUDIES OF ACAMPROSATE Alcohol Alcohol., September 1, 2005; 40(5): 422 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P Overman, C. J Teter, and S. K Guthrie Acamprosate for the Adjunctive Treatment of Alcohol Dependence Ann. Pharmacother., July 1, 2003; 37(7): 1090 - 1099. [Abstract] [Full Text] [PDF]
|
|